Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Cancer Res. 2009 Sep 29;69(19):7811–7818. doi: 10.1158/0008-5472.CAN-09-0986

Figure 6.

Figure 6

EGFR inhibition reduces cell proliferation in some but not all colon cancer cell lines harboring an EGFR 3’UTR mutation. (A). siRNA-mediated downregulation of EGFR in HCT116 and LIM1215 colon cancer cells. (B). siRNA-mediated downregulation of EGFR inhibits growth of LIM1215 but not HCT116 cells in vitro. (C) Targeted inhibition of EGFR using cetuximab inhibits growth of LIM1215 but not HCT116 colon cancer cells in vivo. (D) Comparison of the magnitude of cetuximab-induced growth inhibition in EGFR 3’UTR WT (Caco-2) and mutant (LIM1215 and HCA7) cell lines. Shown is the percentage change of cells in S-phase following 24h treatment with cetuximab (20 µg/ml). Values shown are mean±SEM, n=4 independent experiments.